Clinical Translational Research Core

核心3 -临床翻译研究核心（CTRC）：摘要 临床转化研究核心（CTRC）的目标是促进高质量的临床研究。 翻译研究特别适用于理解，预防和治疗糖尿病，其 并发症和相关代谢紊乱。CTRC支持的研究将利用核心技术 设施和教师在广泛的临床研究方法的专业知识，从概念验证， 临床试验或比较有效性研究，以支持超过35个主要的 在乔斯林做临床研究的调查员。CTRC将支持双向发现之旅 从分子，到模型，再到人，再回到人，同时充当临床观察，台架， 以及成人和儿童患者的人体研究。乔斯林投资了新的设施， 研究中心，将作为新的DRC核心的基础设施。这些设施包括锻炼 培训和检测能力，成人和儿科志愿者的输液和手术室，以及实验室 处理和生物库设施，以获取有价值的人类标本。我们有训练有素的护士， 技术人员进行黄金标准正常血糖，高血糖和低血糖钳夹在生理或 药理学胰岛素浓度;静脉内和口服葡萄糖和混合餐耐量试验;以及其他 代谢测试，以评估胰岛素分泌、胰岛素作用和其他代谢过程， 专门针对糖尿病的研究。新核心的具体目标是：1）实现概念验证和首次人体试验 “T1”转化研究计划，特别关注1型的预测，预防和阻断 （T1 DM）和2型糖尿病（T2 DM）及相关并发症; 2）促进设计、实施和 评价转化为“T2-T3”患者的促发剂启动的临床试验和观察性研究 研究项目侧重于改善和优化T1 DM或T2 DM及相关疾病的治疗 并发症;以及3）生成并维持来自以下的样品的登记和糖尿病特异性生物储存库： 我们独特的乔斯林队列的患者与不寻常的表型，已被广泛的特点。到 为实现这些目标，反恐研究中心将提供一个综合和有效的核心， 多学科糖尿病临床研究，服务包括：a）咨询服务，培训， 指导研究者和研究员进行人类研究的方法和监管流程; B） 在制定和执行糖尿病特定方案方面提供专家专业和技术帮助， 胰岛素分泌、胰岛素作用和运动的复杂评估; c）支持 生物样本和数据管理;以及d）数据分析和解释指南， 调查结果。培训将是新设和常设研究金核心支助的重要组成部分 investigators.总之，这些新举措将有助于将开创性的意见转化为 发现（可能开始在板凳上或床边）到新的糖尿病治愈或治疗机会。

CORE 3 - CLINICAL TRANSLATIONAL RESEARCH CORE (CTRC): ABSTRACT The objective of the Clinical Translational Research Core (CTRC) is to facilitate high-quality clinical translational research specifically applicable to the understanding, prevention and treatment of diabetes, its complications, and related metabolic disorders. Research supported by the CTRC will leverage use of core facilities and faculty with expertise in a broad range in clinical research methods, from proof of concept and physiology, to clinical trials or comparative effectiveness studies to support the more than 35 Principal Investigators doing clinical research at Joslin. The CTRC will support the bi-directional journey of discovery from molecule, to model, to man, and back, while serving as the bridge between clinical observation, bench, and human investigation in adult and pediatric patients. Joslin has invested in new facilities for the Clinical Research Center which will serve as the infrastructure for the new DRC core. These facilities include exercise training and testing capacities, infusion and procedure rooms for adult and pediatric volunteers, and laboratory processing and biobanking facilities for valuable human specimens. We have well-trained nursing and technical staff to perform gold standard euglycemic, hyperglycemic, and hypoglycemic clamps at physiologic or pharmacologic insulin concentrations; intravenous and oral glucose and mixed meal tolerance tests; and other metabolic testing to assess insulin secretion, insulin action, and other metabolic processes for patient centered research specific to diabetes. Specific aims of the new core are to 1) enable proof-of-concept and first-in-man “T1” translational research programs with specific focus on Prediction, Prevention, and Interdiction of type 1 (T1DM) and type 2 diabetes (T2DM) and related complications; 2) facilitate design, implementation, and evaluation of investigator-initiated clinical trials and observational studies for translation to patients in “T2-T3” research programs focused on improving and optimizing treatments of T1DM or T2DM and related complications; and 3) generate and maintain a registry of and a diabetes-specific biorepository of samples from our unique Joslin cohorts of patients with unusual phenotypes that have been extensively characterized. To achieve these aims the CTRC will provide an integrated and efficient core to support collaborative, multidisciplinary diabetes clinical research with services that include: a) consultation services, training, and mentoring of Investigators and fellows in methods and regulatory processes specific to human investigation; b) expert professional and technical help in the development and execution of protocols specific to diabetes and the complex assessments of glycemia, insulin secretion, insulin action, and exercise; c) support for biospecimen samples and data management; and d) guidance for analysis and interpretation of data and findings. Training will be an important component of the core supporting fellows and both new and established investigators. Together, these new initiatives will facilitate the translation of seminal observations and discoveries (which may begin at bench or bedside) into new diabetes cures or therapeutic opportunities.